Market Overview

Goldman Drops Alnylam From Conviction List, But Continues To See 'Blockbuster Potential'

Goldman Drops Alnylam From Conviction List, But Continues To See 'Blockbuster Potential'
Related ALNY
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut
Is Alnylam Pharmaceuticals Finally Ready for Takeoff? (TalkMarkets)

The FDA recently approved Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s patisiran for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.

The genetic, often lethal, disease leads to abnormal buildup of amyloid protein in peripheral nerves, heart and other organs, which results in nerve as well as organ damage.

The Analyst

Goldman Sachs analyst Terence Flynn maintained a Buy rating on Alnylam and lowered the price target from $193 to $155.

The analyst removed Alnylam from Goldman's Americas Conviction List.

The Thesis

The approval was in line with expectations, especially after the Eeuropean Union issued a positive Committee for Medicinal Products for Human Use opinion last month, Flynn said in a Monday note. (See the analyst's track record here.) 

The analyst views the cardio data included in the U.S. label as disappointing, leaving Alnylam at a disadvantage to Pfizer Inc. (NYSE: PFE)'s rival drug candidate Tafamadis.

Full Phase 3 data for Tafamadis is due later this month, Flynn said.

Citing potential headwinds from the patisiran label and likely competition from Pfizer, the analyst lowered the U.S. penetration assumption for patisiran from $2.9 billion to $2.1 billion.

Alnylam shares have lost about 22 percent since they were added to the Conviction List on Dec. 15, 2017 versus a 10-percent gain for the S&P 500 Index, Flynn said. 

Goldman stuck with its Buy rating on Alnylam, as it said competitive risk is already priced into the stock. 

" We ... continue to project blockbuster potential for Patisiran/ALN-TTR-sc02 and believe there is pipeline optionality with data from two additional [Phase 3] assets expected in 2H18-2019," Flynn said. 

The Price Action

Alnylam shares have lost about 23 percent year-to-date.

The stock was trading down 7.36 percent to $90.21 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Latest Ratings for ALNY

Oct 2018BMO CapitalMaintainsOutperformOutperform
Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Biotech Price Target Reiteration Top Stories Analyst Ratings General Best of Benzinga


Related Articles (ALNY + PFE)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Home Depot's Q2 Earnings Preview

Tapestry's Q4 Earnings Preview